Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B7-H4 (VTCN1) is an immune checkpoint protein belonging to the B7 family. It is a type I transmembrane protein that acts as a co-inhibitory ligand for activated lymphocytes, suppressing T cell function by inhibiting proliferation, reducing cytokine production, and/or inducing apoptosis. B7-H4 is overexpressed in various cancers, contributing to tumor immune evasion and is considered a promising target for cancer immunotherapy. Its receptor on T cells is currently unknown.
Inhibition of T-cell activation and proliferation via interaction with an unknown receptor; direct anti-tumor activity; enhancement of anti-tumor immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B7-H4 Protein (B7-H4).